Navigation Links
Sirius Genomics Announces Appointment of Senior Director of Business Development
Date:6/30/2010

VANCOUVER, June 30 /PRNewswire/ - Sirius Genomics, a developer of pharmacogenomic diagnostics, announced today that Kamran Alam has been appointed Senior Director of Business Development.

"Sirius Genomics is on track with our existing products and looking to grow our pipeline. Kam's extensive background in partnering with both global pharmaceutical and medical device companies as well as experience in building collaborations with academic and translational research centers will support our commercialization initiatives and product pipeline development," stated Chris Wagner, President and CEO of Sirius Genomics.

Mr. Alam has over 12 years experience in the biotech and medical device industry, during which time he has worked in several therapeutic areas in the roles of Business Development and Finance. Prior to joining Sirius Genomics, Mr. Alam held positions in business development at the Centre for Drug Research and Development, Angiotech Pharmaceuticals, and AnorMED Inc., and has successfully completed numerous and varied partnering deals, mergers and acquisitions, licensing transactions, and has executed extensive business development initiatives in the U.S., Europe and Asia.

Mr. Alam's professional experience also includes roles with PricewaterhouseCoopers LLP Chartered Accountants. A member of the Institute of Chartered Accountants of British Columbia, Mr. Alam holds an MBA Degree, specializing in International Business and Strategy, and a Bachelor of Science Degree, specializing in Cell Biology and Genetics.

About Sirius Genomics: www.siriusgenomics.com

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable PGx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
9. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
10. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
11. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
(Date:1/19/2017)... 2017  Market Research Future has a half cooked research report ... is growing rapidly and expected to reach USD 450 Million by ... ... Market has been assessed as a swiftly growing market and expected ... the coming future. There has been a tremendous growth in the ...
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... 2016 According to a new market research report "Emotion ... Expression, Voice Recognition), Service, Application Area, End User, And Region - Global Forecast ... USD 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a ... Reading ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):